EUVIMEDEUVIMED entdecken
Open Access

Use of Composite Priors for Assurance of Sequential Therapy Trials: Practical Experiences Using Binary Endpoint Data

Jonathan Wright iD, Li Ye

Pharmaceutical Statistics · 2026

DOI: 10.1002/pst.70125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2026. Verfasst von Jonathan Wright und 1 weiteren Autor:innen. Beteiligte Einrichtung: GSK, London, UK. Hauptthemen laut MEDLINE: Research Design, Endpoint Determination, Clinical Trials, Phase II as Topic, Drug Development. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Accurately calculating assurance can play an important role in quantifying the confidence in the success of a clinical trial. Formulation of prior distributions and the use of assurance can therefore play a vital part in drug development planning and decision‐making. Although approaches in developing priors and calculating probability of success (assurance) have been readily reported, the application for studies incorporating sequential treatment therapy—where multiple medications or therapeutic regimens are administered consecutively to maximise therapeutic efficacy and minimise adverse effects—is less well defined. Challenges relating to eliciting a prior for a single treatment effect across a sequential therapy include reliance on individual experts' subjective beliefs about translating multiple mechanisms of actions into a single overall treatment effect and the inability to capture nuances across and inconsistency in combining individual treatment component effects. In this paper, we outline a comprehensive quantitative framework for developing a composite prior distribution (from individual component priors) and calculating the assurance for study designs involving sequential treatment. We demonstrate how this framework, which employs both prior elicitation and data‐driven prior development methods, was applied in two phase 2 study designs with sequential treatment regimens using a binary endpoint. We also discuss the optimal conditions for these methods and compare the benefits and challenges with a conventional holistic prior elicitation and assurance framework.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignEndpoint DeterminationClinical Trials, Phase II as TopicDrug DevelopmentHumansData Interpretation, StatisticalModels, Statistical

Autor:innen und Institutionen

  • GSK, London, UK.
  • GSK, Upper Providence, Pennsylvania, USA.

ORCID-Profile: Jonathan Wright

Zitieren

APA

Wright, J., & Ye, L. (2026). Use of Composite Priors for Assurance of Sequential Therapy Trials: Practical Experiences Using Binary Endpoint Data. Pharmaceutical Statistics. https://doi.org/10.1002/pst.70125

Vancouver

Wright J, Ye L. Use of Composite Priors for Assurance of Sequential Therapy Trials: Practical Experiences Using Binary Endpoint Data. Pharmaceutical Statistics. 2026. doi:10.1002/pst.70125

BibTeX
@article{Wright2026,
  author = {Wright, Jonathan and Ye, Li},
  title = {Use of Composite Priors for Assurance of Sequential Therapy Trials: Practical Experiences Using Binary Endpoint Data},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  doi = {10.1002/pst.70125}
}
Kostenlos starten →